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Abstract: Hepatic steatosis and chronic kidney disease (CKD) in the advanced stages are closely
related to cardiovascular diseases. Despite the potential connection between early CKD (G1-G3a)
and hepatic steatosis on cardiometabolic risks, few studies have revealed their causal link to ischemic
heart disease (IHD). We prospectively investigated the combined effect of CKD in earlier stages and
hepatic steatosis on incident IHD risk in large-scale, non-diabetic Koreans. Data were assessed from
16,531 participants without diabetes from the Health Risk Assessment Study (HERAS) and Korea
Health Insurance Review and Assessment (HIRA) data. We divided the study population into four
groups according to the existence of early CKD and hepatic steatosis: controls, early CKD only, hep-
atic steatosis only, and both early CKD and hepatic steatosis. We prospectively assessed hazard ratios
(HRs) with 95% confidence intervals (CIs) for IHD using multivariate Cox proportional-hazard regres-
sion models over a 50-month period. During the follow-up period, 326 (2.0%) patients developed IHD.
HRs of IHD in the four groups were 1.00 (controls), 1.26 (95% CI 0.72–2.19), 1.19 (95% CI 0.90–1.57)
and 1.76 (95% CI 1.04–2.97), respectively, after adjusting for potential confounding variables. Even
less than stage 3A, CKD could precede and predict IHD in patients with hepatic steatosis.
Keywords: chronic kidney disease; hepatic steatosis; longitudinal study; ischemic heart disease
1. Introduction
Both chronic kidney disease (CKD) and hepatic steatosis have been increasing over
the decades; simultaneously, the healthcare burden is gradually increasing for managing
each of these diseases. The mean global prevalence of CKD is 13.4% in all stages [1]. CKD
can accelerate hypertension, diabetes, and metabolic syndrome, which are significant risk
factors for cardiovascular diseases (CVDs) [2,3]. However, most studies have shown these
associations in the advanced stages of CKD, including end-stage renal disease (ESRD) [4].
Early detection and management of CKD is a crucial medical issue before progression
to ESRD, which is a progressive comorbidity that results in a range of complications,
including anemia, malnutrition, bone, mineral metabolism disorder, and acidosis [5].
However, many people tend to overlook CKD at an earlier stage because they are often
asymptomatic. In the Third National Health and Nutrition Survey (NHANES III), only 8%
of patients were aware of their diseases among all subjects with a moderately decreased
glomerular filtration rate (GFR) [6].
Hepatic steatosis is a significant public health problem worldwide because of its
high incidence and progression to severe liver diseases, such as steatohepatitis, liver
cirrhosis, and hepatocellular carcinoma [7]. The prevalence of liver steatosis is approx-
imately 25% in adults worldwide [8], while epidemiological studies have shown that
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hepatic steatosis is closely related to obesity, dyslipidemia, and insulin resistance syn-
drome [9,10]. Moreover, hepatic steatosis is associated with extrahepatic complications,
including atherosclerosis [11].
The prevalence of steatosis is higher in patients with CKD than in those without CKD.
CKD is also more prevalent among subjects with hepatic steatosis than in those without
because hepatic steatosis and CKD share common risk factors, such as obesity, hypertension,
diabetes, dyslipidemia, metabolic syndrome, and atherosclerosis [12–15]. The incidence
of simultaneous kidney-liver transplantation has increased gradually over the years [16].
Despite the potential connection between early CKD and steatosis on IHD, few studies
have revealed a causal link between CKD and hepatic steatosis on cardiovascular risks due
to similarity in traditional risk factors, such as hypertension, obesity, dyslipidemia, and
insulin resistance. Accordingly, we prospectively investigated the combined effect of CKD
and hepatic steatosis on incident IHD risk in large-scale, non-diabetic Koreans.
2. Materials and Methods
2.1. Study Population
This study was based on a population-based prospective cohort study of all partici-
pants in the Health Risk Assessment Study (HERAS). The aims and detailed information
of the HERAS dataset were described in a previous study [17]. The cohort of adults aged
more than 20 years in urban areas of South Korea were enrolled to explore surrogate
indicators for cardiometabolic diseases by collecting the risk factors involved in the occur-
rence of cardiometabolic diseases and the lifestyle and health status of Koreans. A total
of 20,530 adults aged 20–80 years were included in the baseline study conducted from
1 November 2006, to 8 June 2010. Subjects meeting any of the following criteria were
excluded: previously diagnosed with angina pectoris, myocardial infarction, ischemic
stroke, diabetes mellitus, or newly developed type 2 diabetes (defined as a fasting plasma
glucose level ≥ 126 mg/dL), chronic kidney disease in advanced stage (G3b–5), alanine
aminotransferase (ALT) ≥ 50 IU/L, aspartate aminotransferase (AST)/ALT > 2, positive
for hepatitis B surface antigen or hepatitis C antibody, presence of liver cirrhosis, and any
missing covariate information. The study protocol was approved by the institutional re-
view board of the Yonsei University College of Medicine. Participants’ data were provided
anonymously after they signed an informed consent form.
2.2. Anthropometric and Laboratory Measurements
Trained medical staff performed the physical examinations according to a standardized
protocol. Bodyweight and height were measured to the nearest 0.1 kg and 0.1 cm, in light
indoor clothing without footwear. Body mass index (BMI) was calculated as the ratio of
body weight in kilograms to the square of height in meters (kg/m2). Systolic and diastolic
blood pressures were measured on the patient’s right arm using a standard mercury
sphygmomanometer in the sitting position after 10 min of rest (Baumanometer, W.A. Baum
Co., Inc., Copiague, NY, USA). The mean arterial pressure was calculated from the systolic
and diastolic blood pressures and were weighted as 1/3 systolic and 2/3 diastolic blood
pressures. Data regarding health-related lifestyle behaviors, such as smoking, drinking,
and physical activity, were obtained through structured questionnaires. Alcohol-related
questions included the types of alcoholic drinks and the amount and frequency of alcohol
consumption. Regular alcohol consumption was defined as alcohol consumption of≥ 140 g
of ethanol per week [18]. Regular exercise was defined as exercise more than three times
per week [19]. Venous blood was sampled from each participant from an antecubital vein
after more than 12-h fast. Fasting blood sugar, lipid profiles, AST, ALT, and creatinine levels
were measured by enzymatic methods using a Hitachi 7600 automated chemistry analyzer
(Hitachi Co., Tokyo, Japan). High-sensitivity C-reactive protein (hs-CRP) concentrations
were measured with a Roche/Hitachi 912 System (Roche Diagnostics, Indianapolis, IN,
USA) using a latex-enhanced immunoturbidimetric method.
Biomedicines 2021, 9, 1358 3 of 9
2.3. Definition of CKD and Hepatic Steatosis
Estimated glomerular filtration rate (eGFR) was calculated using the abbreviated
equation from the Modification of Diet in Renal Disease (MDRD). CKD was defined
as the structural or functional kidney dysfunction, as determined by an eGFR value
< 60 mL/min/1.73 m2 or proteinuria ≥ 1 + according to the Kidney Disease Outcomes
Quality Initiative (KDOQI) CKD classification [20]. The diagnosis of hepatic steatosis
was based on abdominal ultrasonography with a 3.5-Mhz transducer (HDI 5000, Philips,
Bothell, USA). Ultrasonography was performed by the specialized radiologists. There was
no information regarding this study. Patients were diagnosed with fatty liver if more than
two of three findings were detected: deep attenuation, vascular blurring, and increased
liver echogenicity [21].
2.4. Outcomes
The outcomes were acute myocardial infarction (ICD-10 code I21) or angina pectoris
(ICD-10 code I20) after study enrollment. We conducted outcome assessments over the
50 months since the initial enrollment by linking each unique 13-digit identification number
to the Health Insurance Review and Assessment (HIRA) database, which is derived from
the universal coverage system in Korea.
2.5. Statistical Analysis
All statistical analyses were performed using SAS software (version 9.4; SAS Insti-
tute Inc., Cary, NC, USA). Statistical significance was set at p < 0.05. To investigate the
development of IHD, we excluded subjects with IHD and ischemic stroke at baseline.
In addition, subjects with CKD (C3b-C5) and hepatic diseases, including alcoholic liver
disease, viral hepatitis, and liver cirrhosis, were excluded. Furthermore, participants with
type 2 diabetes were excluded, considering their potential effects on both CKD and IHD.
Therefore, we excluded subjects with IHD, CKD in advanced stage, type 2 diabetes, and
pre-existing hepatic disease at baseline. Finally, 16,531 subjects were eligible for the analysis
(Figure 1). We divided the study population into four groups according to the existence
of early CKD and hepatic steatosis: controls (group 1), early CKD only (group 2), hepatic
steatosis only (group 3), and both early CKD and hepatic steatosis (group 4). The inde-
pendent t-test for continuous variables was used to compare baseline characteristics of the
study population with respect to new-onset IHD. The chi-square test categorical variables
were used to evaluate the differences among the four groups. Continuous variables with
normal distributions are presented as mean ± standard deviation (SD). Kaplan–Meier
curves were used to assess the cumulative incidence of IHD. The log-rank test was used to
determine whether the distribution of cumulative ischemic heart disease incidence differed
between the groups. The hazard ratio (HR) and 95% confidence interval (CI) for IHD were
calculated using Cox proportional hazards regression analyses after adjusting for potential
confounding variables.
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Figure 1. Flow chart of the study population selection.
3. Results
A total of 16,531 subjects (8276 men and 8255 women) were enrolled in the final
analysis. Table 1 shows the demographic and biochemical characteristics of the study
participants in both groups. The mean of age, BMI, total cholesterol, triglycerides, high
density-lipoprotein (HDL) cholesterol, and eGFR were 45.1 ± 10.5 years, 23.2 ± 3.0 kg/m2,
188.7 ± 33.3 mg/dL, 120.1 ± 81.8 mg/dL, 53.7 ± 12.7 mg/dL, and 83.7± 13.5, respectively.
The mean values of mean arterial pressure, fasting plasma glucose, total cholesterol, triglyc-
eride, and HDL cholesterol levels were highest in the group with both early CKD and
hepatic steatosis (group 4). The prevalence of early CKD and hepatic steatosis was 5.8%
and 30.1%, respectively.









Early CKD (n = 336) P value
1 Post Hoc 2
Age (years) 44.0 ± 10.5 46.4 ± 12.3 47.1 ± 9.9 50.7 ± 11.0 <0.001 a,b,c,e,f
Male sex (%) 41.6 49.6 68.5 71.7 <0.001 -
BMI (kg/m2) 22.3 ± 2.6 22.3 ± 2.7 25.3 ± 2.7 25.0 ± 2.5 <0.001 b,c,d,e
Systolic BP
(mmHg) 118.8 ± 14.9 121.5 ± 16.0 127.1 ± 14.5 130.3 ± 15.9 <0.001 a,b,c,d,e,f
Diastolic BP
(mmHg) 74.0 ± 9.7 75.9 ± 10.2 79.6 ± 9.6 81.9 ± 9.9 <0.001 a,b,c,d,e,f
AST (IU/L) 19.2 ± 5.0 20.7 ± 5.7 21.6 ± 5.9 23.1 ± 5.9 <0.001 a,b,c,d,e,f
ALT (IU/L) 17.4 ± 7.5 19.1 ± 7.9 24.8 ± 9.5 26.4 ± 9.3 <0.001 a,b,c,d,e,f
GGT (IU/L) 23.9 ± 22.9 30.1 ± 31.7 37.3 ± 31.3 40.3 ± 32.6 <0.001 a,b,c,d,e
FPG (mg/dL) 89.3 ± 8.9 90.7 ± 10.6 95.0 ± 10.0 96.3 ± 10.9 <0.001 a,b,c,d,e










Early CKD (n = 336) P value




183.9 ± 31.8 191.1 ± 35.0 198.5 ± 34.1 205.1 ± 35.0 <0.001 a,b,c,d,e,f
Triglyceride
(mg/dL) 101.0 ± 56.4 105.3 ± 59.7 162.7 ± 110.2 176.7 ± 105.4 <0.001 b,c,d,e,f
HDL-C
(mg/dL) 56.3 ± 12.6 56.8 ± 14.6 47.8 ± 10.2 48.0 ± 11.1 <0.001 b,c,d,e
Hs-CRP (mg/L) 1.1 ± 2.8 1.9 ± 5.2 1.7 ± 4.0 2.1 ± 6.0 <0.001 a,b,c
Current smoker
(%) 21.2 27.8 30.8 26.8 <0.001 -
Alcohol
drinking (%) 41.5 45.4 47.5 45.1 <0.001 -
Regular
exercise (%) 31.8 32.5 29.4 32.5 0.022 -
Hypertension




0.0 ± 0.0 0.0 ± 0.0 1.8 ± 1.2 1.9 ± 1.2 <0.001 b,c,d,e,f
eGFR 85.0 ± 13.3 74.7 ± 16.4 82.7 ± 12.2 71.4 ± 14.5 <0.001 a,b,c,d,e,f
1 p-values were calculated using one-way ANOVA or Pearson’s chi-square test. 2 Post hoc analysis with the Bonferroni method: a, Q1
versus Q2; b, Q1 versus Q3; c, Q1 versus Q4; d, Q2 versus Q3; e, Q2 versus Q4; and f, Q3 versus Q4. 3 Average grade of hepatic steatosis
via ultrasound.
Multivariate Cox regression analysis models were used to evaluate the relative contri-
bution of CKD in earlier stages and hepatic steatosis to the development of IHD (Table 2).
The presence of early CKD with hepatic steatosis was associated with a 76.0% increase
in the risk of developing IHD compared with those without CKD and hepatic steatosis
(HR = 1.76; 95% CI, 1.04–2.97) (model 3). However, the early CKD patients without hepatic
steatosis showed no statistically significant difference in the risk of IHD development
(HR = 1.26; 95% CI, 0.72–2.19). In addition, no significant difference was found in the risk
of IHD when patients with hepatic steatosis were compared with the control group.









Early CKD (n = 336)
New cases of ischemic heart disease, n 164 18 126 18
Mean follow-up, years 2.4 ± 1.1 2.3 ± 0.9 2.3 ± 1.1 2.3 ± 1.0
Pearson-years of follow-up 26,023 1427 10,636 773
Incidence rate/1000 person–years 6.3 12.6 11.8 23.3
Model 1 HR (95% CI) 1.00 (reference) 1.51 (0.93–2.47) 1.47 (1.16–1.86) 2.16 (1.32–3.53)
p value - 0.097 0.001 0.002
Model 2 HR (95% CI) 1.00 (reference) 1.34 (0.77–2.32) 1.29 (0.98–1.69) 1.95 (1.16–3.27)
p value - 0.299 0.068 0.011
Model 3 HR (95% CI) 1.00 (reference) 1.26 (0.72–2.19) 1.19 (0.90–1.57) 1.76 (1.04–2.97)
p value - 0.425 0.230 0.033
Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, body mass index, smoking status, alcohol intake, and physical
activity. Model 3: adjusted for age, sex, body mass index, smoking status, alcohol intake, physical activity, mean arterial blood pres-
sure, fasting plasma glucose, high density-lipoprotein cholesterol, γ-glutamyltransferase, high-sensitivity C-reactive protein level, and
hypertension medication.
During the 50 months of follow-up, new-onset IHD developed in 326 individuals
(2.0%, 326/16,531). Both early CKD and hepatic steatosis (group 4) showed the highest
cumulative incidences of ischemic heart disease up to 50 months after the baseline survey
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(log-rank test, p < 0.001) (Figure 2). The incidence rates per 1000 person-years were 6.3, 12.6,
11.8, and 23.3 in the four groups. Furthermore, to assess the features of the combined effect,
we compared the HR according to the presence of each individual and both together among
all participants. Table 3 shows that the joint effect of early CKD and hepatic steatosis has
synergistic effects on the development of IHD.
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4. Discussion
In this large cohort study, early CKD with hepatic steatosis preceded and predicted
new-onset IHD among individuals without diabetes. These relationships persisted after
adjusting for lifestyle factors, inflammatory markers, and metabolic risk factors.
We found a combined effect of early CKD and liver steatosis on the incidence of IHD.
Previous studies have shown that CKD is independently associated with coronary artery
disease [22,23]. The severity of liver steatosis is positively related to the degree of coronary
atherosclerosis [24]. However, the combined effect of early CKD and steatosis on IHD has
not been thoroughly examined in a longitudinal study. Our results showed that early CKD
with hepatic steatosis was significantly associated with the incidence of IHD, even though
early CKD and hepatic steatosis were not significantly related to the incidence of IHD. This
implies that early CKD can be mechanistically linked to hepatic steatosis.
Although it is challenging to uncover a causal relationship between liver steatosis and
CKD, we can find putative mechanisms by understanding the confounding factors linking
hepatic steatosis and CKD at an earlier stage. The potential pathogenesis contributing
to CKD and steatosis could be nutritional factors, such as fructose and vitamin D. Fruc-
tose is the main constituent of sugar sweeteners. It may lead to kidney and liver injury
through a mechanism mediated by uric acid overproduction. Fructokinase (KRK) is the
first enzyme that metabolizes fructose. The metabolism of fructose to fructose-1-phosphate
by KRK occurs primarily in the liver without any negative feedback. Its metabolism
requires dephosphorylation of ATP with AMP and a fall in intracellular phosphate. Phos-
phate stimulates AMP deaminase (AMPD), catalyzes the degradation of AMP to inosine
monophosphate, and finally produces uric acid. The uric acid released from the liver
circulates to the kidney, thereby damaging the kidney [25]. Furthermore, previous studies
have shown that uric acid-lowering agents have improved fructose-induced CKD and
steatosis [26].
Vitamin D plays many roles in the body, such as immunity, inflammation, regulation of
cell proliferation, and metabolism. Vitamin D deficiency is associated with the pathogenesis
of CKD and hepatic steatosis [27,28]. It is produced on the skin through a UV-mediated
reaction and is metabolized to its active form (1α, 25 (OH)2) through hydroxylation exerted
by the kidney and liver, respectively. Vitamin D regulates the metabolism of free fatty acids
(FFAs) through its action on peroxisome proliferator-activated receptor gamma (PPAR-γ),
improving FFA-induced insulin resistance in vitro [29]. Accordingly, vitamin D deficiency
leads to increased FFA levels. Moreover, the increased FFAs circulate in the blood, induce
fat accumulation in the liver, and promote the development of CKD and steatosis.
Cellular metabolism is orchestrated by the molecular sensors of energy, oxygen, and
nutrients. The dysfunction of some of these sensors, including fetuin-A, adiponectin
and 5′-AMP-activated protein kinase (AMPK), has been involved in the pathogenesis of
CKD and hepatic steatosis. Fetuin-A is an important promoter of insulin resistance. It
is produced by the liver and is secreted into the bloodstream. It binds and inhibits the
insulin receptor tyrosine kinase, leading to insulin resistance. In humans, higher fetuin-A
levels are associated with insulin resistance in patients with CKD [30]. In contrast to
fetuin-A, adiponectin improves insulin sensitivity. Serum fetuin-A and adiponectin levels
are inversely correlated with each other [31]. In the kidney and liver, AMPK is critical
for directing renal podocytes and hepatocytes to detrimental pathways, resulting in end-
organ damage by inflammatory and fibrotic cascades [31]. Consequently, CKD and hepatic
steatosis share a common proinflammatory pathogenesis in disease progression [32,33].
Despite the large cohort dataset, there were several limitations to our study. First, the
study population may not be representative of the general Korean population. Subjects
who participate in health checkups are usually interested in their health problems, leading
to selection bias. Second, the gold standard for the diagnosis of hepatic steatosis is liver
biopsy, but we used ultrasonographic evaluations to define hepatic steatosis because it
has limited availability in health examination settings. Third, this study did not reflect
the effect of changes in the severity of hepatic steatosis or CKD stage, which could affect
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the incidence of IHD during the follow-up period. Lastly, because we did not consider
the type of hypertension medicine, these variables were not fully adjusted for in the
statistical models.
5. Conclusions
In conclusion, even less than stage 3A CKD could predict IHD in patients with hepatic
steatosis. Timely detection of both CKD and steatosis, even in the earlier stages, is critical
to prevent the development of IHD. Further studies are needed to delineate the direct
relationship between liver steatosis and CKD.
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